There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and Aerie Pharma (AERI) with bullish sentiments.
Merck & Company (MRK)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $97.00. The company’s shares closed last Monday at $83.80.
According to TipRanks.com, Goldstein ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.7% and a 31.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Arcus Biosciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $98.75 average price target, implying a 17.8% upside from current levels. In a report issued on October 4, Morgan Stanley also reiterated a Buy rating on the stock with a $99.00 price target.
See today’s analyst top recommended stocks >>
Aerie Pharma (AERI)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma, with a price target of $54.00. The company’s shares closed last Monday at $21.07, close to its 52-week low of $17.51.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -3.5% and a 40.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Collegium Pharmaceutical, and Flexion Therapeutics.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $55.50, a 164.0% upside from current levels. In a report issued on October 4, Mizuho Securities also maintained a Buy rating on the stock with a $63.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
